Document:

CHINA
      KANGTAI CACTUS BIO-TECH, INC.

    

    FIRST
      AMENDED AND RESTATED

    CERTIFICATE
      OF DESIGNATIONS OF PREFERENCES, 

    RIGHTS
      AND LIMITATIONS

    OF
      SERIES A CONVERTIBLE PREFERRED STOCK

    

    The
      undersigned, Jinjiang Wang and Fengxi Lang, do hereby certify that:

     

    1. They
      are
      the President and Secretary, respectively, of China Kangtai Cactus Bio-Tech,
      Inc., a Nevada corporation (the “Company”).

     

    2. The
      Company is authorized to issue 200,000,000 shares of preferred stock, 833,333
      of
      which have been previously issued.

     

    3. The
      following resolutions were duly adopted by the Board of Directors:

     

    WHEREAS,
      the Articles of Incorporation of the Company provides for a class of its
      authorized stock known as preferred stock, comprised of 200,000,000 shares,
      $0.001 par value per share, issuable from time to time in one or more
      series;

     

    WHEREAS,
      the Board of Directors of the Company is authorized to fix the dividend rights,
      dividend rate, voting rights, conversion rights, rights and terms of redemption
      and liquidation preferences of any wholly unissued series of preferred stock
      and
      the number of shares constituting any Series and the designation thereof, of
      any
      of them; 

     

    WHEREAS,
      the Board of Directors of the Company has filed with the Nevada Secretary of
      State on March 21, 2008 a Certificate of Designation which fixed and determined
      the rights, preferences, restrictions and other matters relating to the Series
      A
      Convertible Preferred Stock;

     

    WHEREAS,
      it is the desire of the Board of Directors of the Company, pursuant to its
      authority as aforesaid, to increase the number of shares designated as Series
      A
      Convertible Preferred Stock to up to 1,250,000 shares of the preferred stock
      which the Company has the authority to issue;

     

    WHEREAS,
      the Board of Directors of the Company by unanimous written consent have agreed
      to amend certain provisions of the preferred stock and adopt this First Amended
      and Restated Certificate of Designation of Preferences, Rights and Limitations
      of Series A Convertible Preferred Stock; and 

     

    NOW,
      THEREFORE, BE IT RESOLVED, that Certificate of Designation of Preferences Rights
      and Limitations of Series A Convertible Preferred Stock as filed with the
      Secretary of State of the State of Nevada shall be amended and restated in
      its
      entirety as follows:

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          1 OF 17

        
          

        

      

      
         

      

    

     

    TERMS
      OF PREFERRED STOCK

    

    Section
      1.
      Definitions.
      Capitalized terms used and not otherwise defined herein that are defined in
      the
      Purchase Agreements (as defined below) shall have the meanings given such terms
      in the Purchase Agreements. For the purposes hereof, the following terms shall
      have the following meanings:

     

    “Bankruptcy
      Event”
means
      any of the following events: (a) the Company or any Significant Subsidiary
      (as
      such term is defined in Rule 1.02(s) of Regulation S-X) thereof commences a
      case
      or other proceeding under any bankruptcy, reorganization, arrangement,
      adjustment of debt, relief of debtors, dissolution, insolvency or liquidation
      or
      similar law of any jurisdiction relating to the Company or any Significant
      Subsidiary thereof; (b) there is commenced against the Company or any
      Significant Subsidiary thereof any such case or proceeding that is not dismissed
      within 60 days after commencement; (c) the Company or any Significant Subsidiary
      thereof is adjudicated insolvent or bankrupt or any order of relief or other
      order approving any such case or proceeding is entered; (d) the Company or
      any
      Significant Subsidiary thereof suffers any appointment of any custodian or
      the
      like for it or any substantial part of its property that is not discharged
      or
      stayed within 60 days; (e) the Company or any Significant Subsidiary thereof
      makes a general assignment for the benefit of creditors; (f) the Company or
      any
      Significant Subsidiary thereof calls a meeting of its creditors with a view
      to
      arranging a composition, adjustment or restructuring of its debts; or (g) the
      Company or any Significant Subsidiary thereof, by any act or failure to act,
      expressly indicates its consent to, approval of or acquiescence in any of the
      foregoing or takes any corporate or other action for the purpose of effecting
      any of the foregoing.

     

    “Commission”
means
      the Securities and Exchange Commission.

     

    “Common
      Stock"
      means
      the Company's common stock, par value $0.001 per share, and stock of any other
      class into which such shares may hereafter have been reclassified or
      changed.

     

    “Common
      Stock Equivalents”
means
      any securities of the Company or the Subsidiaries which would entitle the holder
      thereof to acquire at any time Common Stock, including without limitation,
      any
      debt, preferred stock, rights, options, warrants or other instrument that is
      at
      any time convertible into or exchangeable for, or otherwise entitles the holder
      thereof to receive, Common Stock.

     

    “Conversion
      Date”
shall
      have the meaning set forth in Section 6(a).

     

    “Conversion
      Ratio”
shall
      have the meaning set forth in Section 6(a).

     

    “Conversion
      Value”
shall
      have the meaning set forth in Section 6(a).

     

    “Conversion
      Shares”
means,
      collectively, the shares of Common Stock into which the shares of Series A
      Preferred Stock are convertible in accordance with the terms
      hereof.

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          2 OF 17

        
          

        

      

      
         

      

    

     

    “Conversion
      Shares Registration Statement”
means
      a
      registration statement that meets the requirements of the Registration Rights
      Agreement and registers the resale of all Conversion Shares by the Holder,
      who
      shall be named as a “selling stockholder” thereunder, all as provided in the
      Registration Rights Agreement.

     

    “Dilutive
      Issuance”
shall
      have the meaning set forth in Section 7(b) hereof.

     

    “Effective
      Date”
means
      the date that the Conversion Shares Registration Statement is declared effective
      by the Commission.

     

    “Exchange
      Act”
means
      the Securities Exchange Act of 1934, as amended.

     

    “Exempt
      Issuance”
means
      the issuance of (a) shares of Common Stock or options to employees, officers
      or
      directors of the Company pursuant to any stock or option plan duly adopted
      by a
      majority of the non-employee members of the Board of Directors of the Company
      or
      a majority of the members of a committee of non-employee directors established
      for such purpose, (b) securities upon the exercise of or conversion of any
      securities issued hereunder, and of any convertible securities, options or
      warrants issued and outstanding on the date of this Certificate of Designations,
      provided that such securities have not been amended since the date of this
      Certificate of Designations to increase the number of such securities, and
      (c)
      securities issued pursuant to acquisitions or strategic transactions, provided
      any such issuance shall only be to a Person which is, itself or through its
      subsidiaries, an operating company in a business synergistic with the business
      of the Company and in which the Company receives benefits in addition to the
      investment of funds, but shall not include a transaction in which the Company
      is
      issuing securities primarily for the purpose of raising capital or to an entity
      whose primary business is investing in securities.

     

    “Fundamental
      Transaction”
shall
      have the meaning set forth in Section 7(f)(iv) hereof.

     

    “Holder”
shall
      have the meaning given such term in Section 2 hereof.

     

    “Junior
      Securities”
means
      the Common Stock and all other equity or equity equivalent securities of the
      Company other than those securities that are explicitly senior in rights or
      liquidation preference to the Series A Preferred Stock. 

     

    “Original
      Issue Date”
shall
      mean the date of the first issuance of any shares of the Series A Preferred
      Stock regardless of the number of transfers of any particular shares of Series
      A
      Preferred Stock and regardless of the number of certificates which may be issued
      to evidence such Series A Preferred Stock.

     

    “Person”
means
      a
      Company, an association, a partnership, a limited liability company, a business
      association, an individual, a government or political subdivision thereof or
      a
      governmental agency.

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          3 OF 17

        
          

        

      

      
         

      

    

     

    “Purchase
      Agreements”
means
      the Preferred Stock Purchase Agreements, dated as of March 21, 2008 and July
      16,
      2008, to which the Company and the original Holders are parties, as amended,
      modified or supplemented from time to time in accordance with its terms, a
      copy
      of which is on file at the principal offices of the Company.

     

    “Registration
      Rights Agreement”
means
      the Registration Rights Agreement, dated as of the March 21, 2008, to which
      the
      Company and the original Holder are parties, as amended, modified or
      supplemented from time to time in accordance with its terms.

     

    “Securities
      Act”
means
      the Securities Act of 1933, as amended, and the rules and regulations
      promulgated thereunder.

     

    “Series
      A Preferred Stock”
shall
      have the meaning set forth in Section 2.

     

    “Subsidiary”
shall
      mean a Company, limited liability company, partnership, joint venture or other
      business entity of which the Company owns beneficially or of record more than
      19% of the equity interest.

     

    “Trading
      Day”
means
      a
      day on which the Common Stock is traded on a Trading Market.

     

    “Trading
      Market”
means
      the following markets or exchanges on which the Common Stock is listed or quoted
      for trading on the date in question: the Nasdaq SmallCap Market, the American
      Stock Exchange, the New York Stock Exchange, the Nasdaq National Market or
      the
      OTC Bulletin Board.

     

    “Transaction
      Documents”
shall
      have the meaning set forth in the Purchase Agreements.

     

    “VWAP”
means,
      for any date, the price determined by the first of the following clauses that
      applies: (a) if the Common Stock is then listed or quoted on a Trading Market,
      the daily volume weighted average price of the Common Stock for such date (or
      the nearest preceding date) on the primary Trading Market on which the Common
      Stock is then listed or quoted as reported by Bloomberg Financial L.P. (based
      on
      a Trading Day from 9:30 a.m. EST to 4:02 p.m. Eastern Time) using the VAP
      function; (b) if the Common Stock is not then listed or quoted on the
      Trading Market and if prices for the Common Stock are then reported in the
“Pink
      Sheets” published by the National Quotation Bureau Incorporated (or a similar
      organization or agency succeeding to its functions of reporting prices), the
      most recent bid price per share of the Common Stock so reported; or (c) in
      all other cases, the fair market value of a share of Common Stock as determined
      by a nationally recognized-independent appraiser selected in good faith by
      Purchasers holding a majority of the principal amount of Series A Preferred
      Stock then outstanding.

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          4 OF 17

        
          

        

      

      
         

      

       

    

    Section
      2.
      Designation,
      Amount and Par Value.
      The
      series of preferred stock shall be designated as the Company’s Series A
      Convertible Preferred Stock (the “Series
      A Preferred Stock or “Preferred Stock”)
      and
      the number of shares so designated shall be (which shall not be subject to
      increase without the consent of all of the holders of the Series A Preferred
      Stock (each a “Holder”
and
      collectively, the “Holders”).
      Each
      share of Series A Preferred Stock shall have a par value of $0.001 per share.
      Capitalized terms not otherwise defined herein shall have the meaning given
      such
      terms in Section 1 hereof.

     

    Section
      3.
      Dividends
      and Other Distributions.
      No
      dividends shall be payable with respect to the Series A Preferred Stock. No
      dividends shall be payable with respect to the Common Stock while the Series
      A
      Preferred Stock is outstanding. The Common Stock shall not be redeemed while
      the
      Series A Preferred Stock is outstanding.

     

    Section
      4.
      Voting
      Rights.
      The
      Series A Preferred Stock shall have no voting rights. However, so long as any
      shares of Series A Preferred Stock are outstanding, the Company shall not,
      without the affirmative approval of the Holders of the shares of the Series
      A
      Preferred Stock then outstanding, (a) alter or change adversely the powers,
      preferences or rights given to the Series A Preferred Stock or alter or amend
      this Certificate of Designation, (b) authorize or create any class of stock
      ranking as to dividends or distribution of assets upon a Liquidation (as defined
      in Section 5) senior to or otherwise pari passu with the Series A Preferred
      Stock, or any of preferred stock possessing greater voting rights or the right
      to convert at a more favorable price than the Series A Preferred Stock, (c)
      amend its certificate or articles of incorporation or other charter documents
      in
      breach of any of the provisions hereof, (d) increase the authorized number
      of
      shares of Series A Preferred Stock, or (e) enter into any agreement with respect
      to the foregoing.

     

    Section
      5.
      Liquidation.
      Upon
      any liquidation, dissolution or winding-up of the Company, whether voluntary
      or
      involuntary (a “Liquidation”),
      the
      Holders shall be entitled to receive out of the assets of the Company, whether
      such assets are capital or surplus, for each share of Series A Preferred Stock
      an amount equal to $0.60 (the “Liquidation
      Value”)
      before
      any distribution or payment shall be made to the holders of any Junior
      Securities, and if the assets of the Company shall be insufficient to pay in
      full such amounts, then the entire assets to be distributed to the Holders
      shall
      be distributed among the Holders ratably in accordance with the respective
      amounts that would be payable on such shares if all amounts payable thereon
      were
      paid in full. At the election of a Holder made by written notice delivered
      to
      the Company at least two (2) business days prior to the effective date of the
      subject transaction, as to the shares of Series A Preferred Stock held by such
      Holder, a Fundamental Transaction (excluding for purposes of this Section 5
      any
      Fundamental Transaction described in Section 7(f)(iv)(A) or 7(f)(iv)(B)) or
      Change of Control shall be treated as a Liquidation. 

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          5 OF 17

        
          

        

      

      
         

      

       

    

    Section
      6.
      Conversion.

     

    a) Conversions
      at Option of Holder.
      Each
      share of Series A Preferred Stock shall be initially convertible (subject to
      the
      limitations set forth in Section 6(c)), into one (1) share of Common Stock
      (as
      adjusted as provided below, the “Conversion
      Ratio”)
      at the
      option of the Holders, at any time and from time to time from and after the
      Original Issue Date. Holders shall effect conversions by providing the Company
      with the form of conversion notice attached hereto as Annex
      A
      (a
“Notice
      of Conversion”)
      as
      fully and originally executed by the Holder, together with the delivery by
      the
      Holder to the Company of the stock certificate(s) representing the number of
      shares of Series A Preferred Stock so converted, with such stock certificates
      being duly endorsed in full for transfer to the Company or with an applicable
      stock power duly executed by the Holder in the manner and form as deemed
      reasonable by the transfer agent of the Common Stock. Each Notice of Conversion
      shall specify the number of shares of Series A Preferred Stock to be converted,
      the number of shares of Series A Preferred Stock owned prior to the conversion
      at issue, the number of shares of Series A Preferred Stock owned subsequent
      to
      the conversion at issue, the stock certificate number and the shares of Series
      A
      Preferred Stock represented thereby which are accompanying the Notice of
      Conversion, and the date on which such conversion is to be effected, which
      date
      may not be prior to the date the Holder delivers such Notice of Conversion
      and
      the applicable stock certificates to the Company by overnight delivery service
      (the “Conversion
      Date”).
      If no
      Conversion Date is specified in a Notice of Conversion, the Conversion Date
      shall be the Trading Day immediately following the date that such Notice of
      Conversion and applicable stock certificates are received by the Company. The
      calculations and entries set forth in the Notice of Conversion shall control
      in
      the absence of manifest or mathematical error. Shares of Series A Preferred
      Stock converted into Common Stock in accordance with the terms hereof shall
      be
      canceled and may not be reissued. The initial value of the Series A Preferred
      Stock on the Conversion Date shall be equal to $0.60 per share (as adjusted
      pursuant to Section 7 or otherwise as provided herein, the “Conversion
      Value”).
      If
      the initial Conversion Value is adjusted pursuant to Section 7 or as otherwise
      provided herein, the Conversion Ratio shall likewise be adjusted and the new
      Conversion Ratio shall equal the Liquidation Value divided by the new Conversion
      Value. Thereafter, subject to any further adjustments in the Conversion Value,
      each share of Series A Preferred Stock shall be initially convertible into
      that
      number of shares of Common Stock equal to the new Conversion Ratio.

     

    b) Automatic
      Conversion Upon Change of Control.

     

    i. Subject
      to Section 5, all of the outstanding shares of Series A Preferred Stock shall
      be
      automatically converted into the Conversion Shares upon the close of business
      on
      the business day immediately preceding the date fixed for consummation of any
      transaction resulting in a Change of Control of the Company (an "Automatic
      Conversion Event"). A "Change in Control" means a consolidation or merger of
      the
      Company with or into another company or entity in which the Company is not
      the
      surviving entity or the sale of all or substantially all of the assets of the
      Company to another company or entity not controlled by the then existing
      stockholders of the Company in a transaction or series of transactions. The
      Company shall not be obligated to issue certificates evidencing the Conversion
      Shares unless certificates evidencing the shares of Series A Preferred Stock
      so
      converted are either delivered to the Company or its transfer agent or the
      holder notifies the Company or its transfer agent in writing that such
      certificates have been lost, stolen, or destroyed and executes an agreement
      satisfactory to the Company to indemnify the Company from any loss incurred
      by
      it in connection therewith. Upon the conversion of the Series A Preferred Stock
      pursuant to this Section 6(b)(i), the Company shall promptly send written notice
      thereof, by hand delivery or by overnight delivery, to the holder of record
      of
      all of the Series A Preferred Stock at its address then shown on the records
      of
      the Company, which notice shall state that certificates evidencing shares of
      Series A Preferred Stock must be surrendered at the office of the Company (or
      of
      its transfer agent for the Common Stock, if applicable).

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          6 OF 17

        
          

        

      

      
         

      

       

    

    c) Beneficial
      Ownership Limitation.
      Except
      as provided in Section 6(b) above, the Company shall not effect any conversion
      of the Series A Preferred Stock, and the Holder shall not have the right to
      convert any portion of the Series A Preferred Stock to the extent that after
      giving effect to such conversion, the Holder (together with the Holder’s
      affiliates), as set forth on the applicable Notice of Conversion, would
      beneficially own in excess of 4.9% of the number of shares of the Common Stock
      outstanding immediately after giving effect to such conversion.  For
      purposes of the foregoing sentence, the number of shares of Common Stock
      beneficially owned by the Holder and its affiliates shall include the number
      of
      shares of Common Stock issuable upon conversion of the Series A Preferred Stock
      with respect to which the determination of such sentence is being made, but
      shall exclude the number of shares of Common Stock which would be issuable
      upon
      (A) conversion of the remaining, nonconverted shares of Series A Preferred
      Stock
      beneficially owned by the Holder or any of its affiliates, so long as such
      shares of Series A Preferred Stock are not convertible within sixty (60) days
      from the date of such determination, and (B) exercise or conversion of the
      unexercised or nonconverted portion of any other securities of the Company
      (including the Warrants) subject to a limitation on conversion or exercise
      analogous to the limitation contained herein beneficially owned by the Holder
      or
      any of its affiliates, so long as such other securities of the Company are
      not
      exercisable nor convertible within sixty (60) days from the date of such
      determination.  For purposes of this Section 6(c), in determining the
      number of outstanding shares of Common Stock, the Holder may rely on the number
      of outstanding shares of Common Stock as reflected in the most recent of the
      following: (A) the Company’s most recent quarterly reports, Form 10-Q, Form
      10-QSB, Annual Reports, Form 10-K, or Form 10-KSB, as the case may be, as filed
      with the Commission under the Exchange Act (B) a more recent public announcement
      by the Company or (C) any other written notice by the Company or the Company’s
      transfer agent setting forth the number of shares of Common Stock
      outstanding.  Upon the written or oral request of the Holder, the Company
      shall within two (2) Trading Days confirm orally and in writing to the Holder
      the number of shares of Common Stock then outstanding.  In any case, the
      number of outstanding shares of Common Stock shall be determined after giving
      effect to the conversion or exercise of securities of the Company, including
      the
      Series A Preferred Stock, by the Holder or its affiliates since the date as
      of
      which such number of outstanding shares of Common Stock was publicly reported
      by
      the Company. This Section 6(c) may be waived or amended only with the consent
      of
      the Holders of all of the Series A Preferred Stock and the consent of the
      holders of a majority of the shares of outstanding Common Stock of the Company
      who are not Affiliates. For the purpose of the immediately preceding sentence,
      the term “Affiliate” shall mean any person: (a) that directly or indirectly,
      through one or more intermediaries controls, or is controlled by, or is under
      common control with the Company, or (b) who beneficially owns (i) any shares
      of
      Series A Preferred Stock, or (ii) the Company’s Common Stock Purchase Warrant(s)
      dated March 21, 2008 and July 16, 2008. For purposes of this Section 6(c),
      beneficial ownership shall be calculated in accordance with Section 13(d) of
      the
      Exchange Act.

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          7 OF 17

        
          

        

      

      
         

      

       

    

    d) Mechanics
      of Conversion

     

    i. Delivery
      of Certificate Upon Conversion.
      Except
      as otherwise set forth herein, not later than three Trading Days after each
      Conversion Date (the “Share
      Delivery Date”),
      the
      Company shall deliver to the Holder (A) a certificate or certificates which,
      after the Effective Date, shall be free of restrictive legends and trading
      restrictions (other than those required by the Purchase Agreements) representing
      the number of shares of Common Stock being acquired upon the conversion of
      shares of Series A Preferred Stock, and (B) a bank check in the amount of
      accrued and unpaid dividends (if the Company has elected or is required to
      pay
      accrued dividends in cash). After the Effective Date, the Company shall, upon
      request of the Holder, deliver any certificate or certificates required to
      be
      delivered by the Company under this Section electronically through the
      Depository Trust Company or another established clearing Company performing
      similar functions. If in the case of any Notice of Conversion such certificate
      or certificates are not delivered to or as directed by the applicable Holder
      by
      the third Trading Day after the Conversion Date, the Holder shall be entitled
      to
      elect by written notice to the Company at any time on or before its receipt
      of
      such certificate or certificates thereafter, to rescind such conversion, in
      which event the Company shall immediately return the certificates representing
      the shares of Series A Preferred Stock tendered for conversion.

     

    ii. Obligation
      Absolute; Partial Liquidated Damages.
      The
      Company’s obligations to issue and deliver the Conversion Shares upon conversion
      of Series A Preferred Stock in accordance with the terms hereof are absolute
      and
      unconditional, irrespective of any action or inaction by the Holder to enforce
      the same, any waiver or consent with respect to any provision hereof, the
      recovery of any judgment against any Person or any action to enforce the same,
      or any setoff, counterclaim, recoupment, limitation or termination, or any
      breach or alleged breach by the Holder or any other Person of any obligation
      to
      the Company or any violation or alleged violation of law by the Holder or any
      other person, and irrespective of any other circumstance which might otherwise
      limit such obligation of the Company to the Holder in connection with the
      issuance of such Conversion Shares. In the event a Holder shall elect to convert
      any or all of its Series A Preferred Stock, the Company may not refuse
      conversion based on any claim that such Holder or any one associated or
      affiliated with the Holder of has been engaged in any violation of law,
      agreement or for any other reason, unless, an injunction from a court, on
      notice, restraining and or enjoining conversion of all or part of this Series
      A
      Preferred Stock shall have been sought and obtained and the Company posts a
      surety bond for the benefit of the Holder in the amount of 150% of the
      Conversion Value of Series A Preferred Stock outstanding, which is subject
      to
      the injunction, which bond shall remain in effect until the completion of
      arbitration/litigation of the dispute and the proceeds of which shall be payable
      to such Holder to the extent it obtains judgment. 

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          8 OF 17

        
          

        

      

      
         

      

       

    

    iii. Compensation
      for Buy-In on Failure to Timely Deliver Certificates Upon
      Conversion.
      If the
      Company fails to deliver to the Holder such certificate or certificates pursuant
      to Section 6(d)(i) by a Share Delivery Date, and if after such Share Delivery
      Date the Holder purchases (in an open market transaction or otherwise) Common
      Stock to deliver in satisfaction of a sale by such Holder of the Conversion
      Shares which the Holder was entitled to receive upon the conversion relating
      to
      such Share Delivery Date (a “Buy-In”),
      then
      the Company shall pay in cash to the Holder the amount by which (x) the Holder's
      total purchase price (including brokerage commissions, if any) for the Common
      Stock so purchased exceeds (y) the product of (1) the aggregate number of shares
      of Common Stock that such Holder was entitled to receive from the conversion
      at
      issue multiplied by (2) the price at which the sell order giving rise to such
      purchase obligation was executed. For example, if the Holder purchases Common
      Stock having a total purchase price of $11,000 to cover a Buy-In with respect
      to
      an attempted conversion of shares of Series A Preferred Stock with respect
      to
      which the aggregate sale price giving rise to such purchase obligation is
      $10,000, under clause (A) of the immediately preceding sentence the Company
      shall be required to pay the Holder $1,000. The Holder shall provide the Company
      written notice indicating the amounts payable to the Holder in respect of the
      Buy-In, together with applicable confirmations and other evidence reasonably
      requested by the Company. Nothing herein shall limit a Holder’s right to pursue
      any other remedies available to it hereunder, at law or in equity including,
      without limitation, a decree of specific performance and/or injunctive relief
      with respect to the Company's failure to timely deliver certificates
      representing shares of Common Stock upon conversion of the shares of Series
      A
      Preferred Stock as required pursuant to the terms hereof.

     

    iv. Reservation
      of Shares Issuable Upon Conversion.
      The
      Company covenants that it will at all times reserve and keep available out
      of
      its authorized and unissued shares of Common Stock solely for the purpose of
      issuance upon conversion of the Series A Preferred Stock, each as herein
      provided, free from preemptive rights or any other actual contingent purchase
      rights of persons other than the Holders, not less than such number of shares
      of
      the Common Stock as shall (subject to any additional requirements of the Company
      as to reservation of such shares set forth in the Purchase Agreements) be
      issuable (taking into account the adjustments and restrictions of Section 7)
      upon the conversion of all outstanding shares of Series A Preferred Stock.
      The
      Company covenants that all shares of Common Stock that shall be so issuable
      shall, upon issue, be duly and validly authorized, issued and fully paid,
      nonassessable and, if the Conversion Shares Registration Statement is then
      effective under the Securities Act, registered for public sale in accordance
      with such Conversion Shares Registration Statement.

     

    v. Fractional
      Shares.
      Upon a
      conversion hereunder, the Company shall not be required to issue stock
      certificates representing fractions of shares of the Common Stock.

     

    vi. Transfer
      Taxes.
      The
      issuance of certificates for shares of the Common Stock on conversion of the
      Series A Preferred Stock shall be made without charge to the Holders thereof
      for
      any documentary stamp or similar taxes that may be payable in respect of the
      issue or delivery of such certificate, provided that the Company shall not
      be
      required to pay any tax that may be payable in respect of any transfer involved
      in the issuance and delivery of any such certificate upon conversion in a name
      other than that of the Holder of such shares of Series A Preferred Stock so
      converted and the Company shall not be required to issue or deliver such
      certificates unless or until the person or persons requesting the issuance
      thereof shall have paid to the Company the amount of such tax or shall have
      established to the satisfaction of the Company that such tax has been
      paid.

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          9 OF 17

        
          

        

      

      
         

      

       

    

    Section
      7.
       Certain
      Adjustments.

    

    a) Stock
      Dividends and Stock Splits.
      If the
      Company, at any time while the Series A Preferred Stock is outstanding: (A)
      shall pay a stock dividend or otherwise make a distribution or distributions
      on
      shares of its Common Stock or any other equity or equity equivalent securities
      payable in shares of Common Stock (which, for avoidance of doubt, shall not
      include any shares of Common Stock issued by the Company pursuant to this Series
      A Preferred Stock), (B) subdivide outstanding shares of Common Stock into a
      larger number of shares, (C) combine (including by way of reverse stock split)
      outstanding shares of Common Stock into a smaller number of shares, or (D)
      issue
      by reclassification of shares of the Common Stock any shares of capital stock
      of
      the Company, then the Conversion Value shall be multiplied by a fraction of
      which the numerator shall be the number of shares of Common Stock (excluding
      treasury shares, if any) outstanding before such event and of which the
      denominator shall be the number of shares of Common Stock outstanding after
      such
      event. Any adjustment made pursuant to this Section shall become effective
      immediately after the record date for the determination of stockholders entitled
      to receive such dividend or distribution and shall become effective immediately
      after the effective date in the case of a subdivision, combination or
      re-classification.

     

    b) Price
      Adjustment. From
      the
      date hereof until such time as no Purchaser holds any of the Securities, the
      Company closes on the sale of a note or notes, shares of Common Stock, or shares
      of any class of Preferred Stock at a price per share of Common Stock, or with
      a
      conversion right to acquire Common Stock at a price per share of Common Stock,
      that is less than the Conversion Price (as adjusted to the capitalization per
      share as of the March 21, 2008, following any stock splits, stock dividends,
      or
      the like) (collectively, the “Subsequent Conversion Price”), the Company shall
      make a post-Closing adjustment in the Conversion Price so that the effective
      price per share paid by the Investor is adjusted to a price determined by
      multiplying such Conversion Price by a fraction, the numerator of which shall
      be
      the number of shares of Common Stock Outstanding (defined below) immediately
      prior to such issuance plus the number of shares of Common Stock that the
      aggregate consideration received by the Company for such issuance would purchase
      at such Conversion Price; and the denominator of which shall be the number
      of
      shares of Common Stock Outstanding (as defined below) immediately prior to
      such
      issuance plus the number of shares issued at such issuance. For purposes of
      this
Section
      7,
      the
      term “Common Stock Outstanding” shall mean and include the following: (1)
      outstanding Common Stock, (2) Common Stock issuable upon conversion of
      outstanding Preferred Stock, (3) Common Stock issuable upon exercise of
      outstanding warrants. Shares described in (1) through (4) above shall be
      included whether vested or unvested, whether contingent or non-contingent and
      whether exercisable or not yet exercisable.

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          10 OF 17

        
          

        

      

      
         

      

       

    

    c) Subsequent
      Equity Sales.
      From
      the date hereof until such time as no Purchaser holds any of the Securities,
      the
      Company shall be prohibited from effecting or entering into an agreement to
      effect any Subsequent Financing involving a “Variable Rate Transaction” or an
“MFN Transaction” (each as defined below). The term “Variable Rate Transaction”
shall mean a transaction in which the Company issues or sells (i) any debt
      or
      equity securities that are convertible into, exchangeable or exercisable for,
      or
      include the right to receive additional shares of Common Stock either (A) at
      a
      conversion, exercise or exchange rate or other price that is based upon and/or
      varies with the trading prices of or quotations for the shares of Common Stock
      at any time after the initial issuance of such debt or equity securities, or
      (B)
      with a conversion, exercise or exchange price that is subject to being reset
      at
      some future date after the initial issuance of such debt or equity security
      or
      upon the occurrence of specified or contingent events directly or indirectly
      related to the business of the Company or the market for the Common Stock.
      The
      term “MFN Transaction” shall mean a transaction in which the Company issues or
      sells any securities in a capital raising transaction or series of related
      transactions which grants to an investor the right to receive additional shares
      based upon future transactions of the Company on terms more favorable than
      those
      granted to such investor in such offering. Any Purchaser shall be entitled
      to
      obtain injunctive relief against the Company to preclude any such issuance,
      which remedy shall be in addition to any right to collect damages.
      Notwithstanding the foregoing, this Section 6.184 shall not apply in respect
      of
      an Exempt Issuance, except that no Variable Rate Transaction or MFN Transaction
      shall be an Exempt Issuance, nor shall this Section 6.14 prevent the Company
      from potentially granting anti-dilution protection to any potential future
      investors in the Company.

     

    d) Price
      Adjustment Based on Earnings Per Share.
      In the
      event the Company earns between $0.0670 and $0.0335 (50% Decline) per share
      (where such earnings in this paragraph shall always be defined as earnings
      on a
      pre tax fully diluted basis (including dilution from any options, warrants
      and
      convertible securities) as reported for the audited sixth months ended June
      30,
      2008 from continuing operations before any non-cash items the then current
      Conversion Price to the Investor at the time the audited numbers are reported
      to
      the SEC shall be decrease proportionately by 0% if the pre tax earnings (for
      first six months ended June 30, 2008) are $0.0670 per share or greater and
      by
      50% if the pre tax earnings (for first six months ended June 30, 2008) are
      $0.0335 per share (50% decrease). For example if the earnings are $ 0.0536
      per
      share or less (20% Decline) then the then current Conversion Price to the
      investor shall be reduced by 20%. Such adjustment shall be made automatically
      within five business days of the audited numbers being reported to the SEC.
      

     

    In
      the
      event the Company earns between $0.1559 and $0.0780 (50% Decline) per share
      (where such earnings in this paragraph shall always be defined as earnings
      on a
      pre tax fully diluted basis (including dilution from any options, warrants
      and
      convertible securities) as reported for the audited fiscal year ending 2008
      from
      continuing operations before any non-cash items the then current Conversion
      Price to the Investor at the time the audited numbers are reported to the SEC
      shall be decrease proportionately by 0% if the pre tax earnings are $0.1559
      per
      share or greater and by 50% if the pre tax earnings are $0.0780 per share (50%
      decrease). For example if the earnings are $ 0.1247 per share or less (20%
      Decline) then the then current Conversion Price to the investor shall be reduced
      by 20%. Such adjustment shall be made automatically within five business days
      of
      the audited numbers being reported to the SEC. 

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          11 OF 17

        
          

        

      

      
         

      

       

    

    e) Pro
      Rata Distributions.
      If the
      Company, at any time while Series A Preferred Stock is outstanding, shall
      distribute to all holders of Common Stock (and not to Holders) evidences of
      its
      indebtedness or assets or rights or warrants to subscribe for or purchase any
      security, then in each such case the Conversion Value shall be determined by
      multiplying such Conversion Value in effect immediately prior to the record
      date
      fixed for determination of stockholders entitled to receive such distribution
      by
      a fraction of which the denominator shall be the VWAP determined as of the
      record date mentioned above, and of which the numerator shall be such VWAP
      on
      such record date less the then fair market value at such record date of the
      portion of such assets or evidence of indebtedness so distributed applicable
      to
      one outstanding share of the Common Stock as determined by the Board of
      Directors in good faith. In either case the adjustments shall be described
      in a
      statement provided to the Holders of the portion of assets or evidences of
      indebtedness so distributed or such subscription rights applicable to one share
      of Common Stock. Such adjustment shall be made whenever any such distribution
      is
      made and shall become effective immediately after the record date mentioned
      above.

     

    f) Calculations.
      All
      calculations under this Section 7 shall be made to the nearest cent or the
      nearest 1/100th of a share, as the case may be. The number of shares of Common
      Stock outstanding at any given time shall not include shares owned or held
      by or
      for the account of the Company, and the description of any such shares of Common
      Stock shall be considered on issue or sale of Common Stock. For purposes of
      this
      Section 7, the number of shares of Common Stock deemed to be issued and
      outstanding as of a given date shall be the sum of the number of shares of
      Common Stock (excluding treasury shares, if any) actually issued and
      outstanding.

     

    g) Notice
      to Holders.

     

    i. Adjustment
      to Conversion Price.
      Whenever the Conversion Value is adjusted pursuant to any of this Section 7,
      the
      Company shall promptly mail to each Holder a notice setting forth the Conversion
      Value after such adjustment and setting forth a brief statement of the facts
      requiring such adjustment. If the Company issues a variable rate security,
      despite the prohibition thereon in the Purchase Agreements, the Company shall
      be
      deemed to have issued Common Stock or Common Stock Equivalents at the lowest
      possible conversion or exercise price at which such securities may be converted
      or exercised in the case of a Variable Rate Transaction (as defined in the
      Purchase Agreements), or the lowest possible adjustment price in the case of
      an
      MFN Transaction (as defined in the Purchase Agreements).

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          12 OF 17

        
          

        

      

      
         

      

       

    

    ii. Notices
      of Other Events.
      If (A)
      the Company shall declare a dividend (or any other distribution) on the Common
      Stock; (B) the Company shall declare a redemption of the Common Stock; (C)
      the
      Company shall authorize the granting to all holders of the Common Stock rights
      or warrants to subscribe for or purchase any shares of capital stock of any
      class or of any rights; (D) the approval of any stockholders of the Company
      shall be required in connection with any reclassification of the Common Stock
      or
      any Fundamental Transaction, (E) the
      Company shall authorize the voluntary or involuntary dissolution, liquidation
      or
      winding up of the affairs of the Company; then in each case, the Company shall
      cause to be filed at each office or agency maintained for the purpose of
      conversion of the Series A Preferred Stock, and shall cause to be mailed
      to
      the Holders at their last addresses as they shall appear upon the stock
      books of
      the
      Company, at least 30 calendar days prior to the applicable record or effective
      date hereinafter specified, a notice stating (x)
      the
      date on which a record is to be taken for the purpose of such dividend,
      distribution, redemption, rights or warrants, or if a record is not to be taken,
      the date as of which the holders of the Common Stock of record to be entitled
      to
      such dividend, distributions, redemption, rights or warrants are to be
      determined or (y) the date on which such reclassification is expected to become
      effective or close, and the date as of which it is expected that holders of
      the
      Common Stock of record shall be entitled to exchange their shares of the Common
      Stock for securities, cash or other property deliverable upon such
      reclassification or Fundamental Transaction; provided,
      that
      the failure to mail such notice or any defect therein or in the mailing thereof
      shall not affect the validity of the corporate action required to be specified
      in such notice.

     

    iii. Exempt
      Issuance.
      Notwithstanding the foregoing, no adjustment will be made under this Section
      7
      in respect of an Exempt Issuance.

     

    iv. Fundamental
      Transaction.
      If, at
      any time while this Series A Preferred Stock is outstanding, (A) the Company
      effects any merger or consolidation of the Company with or into another Person,
      (B) the Company effects any sale of all or substantially all of its assets
      in
      one or a series of related transactions, (C) any tender offer or exchange offer
      (whether by the Company or another Person) is completed pursuant to which
      holders of Common Stock are permitted to tender or exchange their shares for
      other securities, cash or property, or (D) the Company effects any
      reclassification of the Common Stock or any compulsory share exchange pursuant
      to which the Common Stock is effectively converted into or exchanged for other
      securities, cash or property (in any such case, a “Fundamental
      Transaction”),
      then
      upon any subsequent conversion of this Series A Preferred Stock, the Holder
      shall have the right to receive, for each Conversion Share that would have
      been
      issuable upon such conversion absent such Fundamental Transaction, the same
      kind
      and amount of securities, cash or property as it would have been entitled to
      receive upon the occurrence of such Fundamental Transaction if it had been,
      immediately prior to such Fundamental Transaction, the holder of one share
      of
      Common Stock (the “Alternate
      Consideration”).
      For
      purposes of any such conversion, the determination of the Conversion Price
      shall
      be appropriately adjusted to apply to such Alternate Consideration based on
      the
      amount of Alternate Consideration issuable in respect of one share of Common
      Stock in such Fundamental Transaction, and the Company shall apportion the
      Conversion Price among the Alternate Consideration in a reasonable manner
      reflecting the relative value of any different components of the Alternate
      Consideration. If holders of Common Stock are given any choice as to the
      securities, cash or property to be received in a Fundamental Transaction, then
      the Holder shall be given the same choice as to the Alternate Consideration
      it
      receives upon any conversion of this Series A Preferred Stock following such
      Fundamental Transaction. To the extent necessary to effectuate the foregoing
      provisions, any successor to the Company or surviving entity in such Fundamental
      Transaction shall file a new Certificate of Designations with the same terms
      and
      conditions and issue to the Holder new preferred stock consistent with the
      foregoing provisions and evidencing the Holder’s right to convert such preferred
      stock into Alternate Consideration. The terms of any agreement pursuant to
      which
      a Fundamental Transaction is effected shall include terms requiring any such
      successor or surviving entity to comply with the provisions of this paragraph
      (f)(iv) and insuring that this Series A Preferred Stock (or any such replacement
      security) will be similarly adjusted upon any subsequent transaction analogous
      to a Fundamental Transaction.

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          13 OF 17

        
          

        

      

      
         

      

       

    

    Section
      8.
       Miscellaneous.
      

     

    a) Notices.
      Any and
      all notices or other communications or deliveries to be provided by the Holders
      hereunder, including, without limitation, any Notice of Conversion, shall be
      in
      writing and delivered personally, by facsimile, sent by a nationally recognized
      overnight courier service, addressed to the Company, at the address provided
      in
      the Purchase Agreements, facsimile number +86 451 57351551,
      Attn: Jinjiang
      Wang or such other address or facsimile number as the Company may specify for
      such purposes by notice to the Holders delivered in accordance with this
      Section. Any and all notices or other communications or deliveries to be
      provided by the Company hereunder shall be in writing and delivered personally,
      by facsimile, sent by a nationally recognized overnight courier service
      addressed to each Holder at the facsimile telephone number or address of such
      Holder appearing on the books of the Company, or if no such facsimile telephone
      number or address appears, at the principal place of business of the Holder.
      Any
      notice or other communication or deliveries hereunder shall be deemed given
      and
      effective on the earliest of (i) the date of transmission, if such notice or
      communication is delivered via facsimile at the facsimile telephone number
      specified in this Section prior to 5:30 p.m. (New York City time), (ii) the
      date
      after the date of transmission, if such notice or communication is delivered
      via
      facsimile at the facsimile telephone number specified in this Section later
      than
      5:30 p.m. (New York City time) on any date and earlier than 11:59 p.m. (New
      York
      City time) on such date, (iii) the second Business Day following the date of
      mailing, if sent by nationally recognized overnight courier service, or (iv)
      upon actual receipt by the party to whom such notice is required to be
      given. 

     

    b) Absolute
      Obligation.
      Except
      as expressly provided herein, no provision of this Certificate of Designation
      shall alter or impair the obligation of the Company, which is absolute and
      unconditional, to pay the liquidated damages (if any) on, the shares of Series
      A
      Preferred Stock at the time, place, and rate, and in the coin or currency,
      herein prescribed. 

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          14 OF 17

        
          

        

      

      
         

      

       

    

    c) Lost
      or Mutilated Preferred Stock Certificate.
      If a
      Holder’s Series A Preferred Stock certificate shall be mutilated, lost, stolen
      or destroyed, the Company shall execute and deliver, in exchange and
      substitution for and upon cancellation of a mutilated certificate, or in lieu
      of
      or in substitution for a lost, stolen or destroyed certificate, a new
      certificate for the shares of Series A Preferred Stock so mutilated, lost,
      stolen or destroyed but only upon receipt of evidence of such loss, theft or
      destruction of such certificate, and of the ownership thereof, and indemnity,
      if
      requested, all reasonably satisfactory to the Company.

     

    d) Next
      Business Day.
      Whenever any payment or other obligation hereunder shall be due on a day other
      than a Business Day, such payment shall be made on the next succeeding Business
      Day.

     

    e) Headings.
      The
      headings contained herein are for convenience only, do not constitute a part
      of
      this Certificate of Designations and shall not be deemed to limit or affect
      any
      of the provisions hereof.

     

    RESOLVED,
      FURTHER,
      that
      the Chairman, the president or any vice-president, and the secretary or any
      assistant secretary, of the Company be and they hereby are authorized and
      directed to prepare and file a Certificate of Designation of Preferences, Rights
      and Limitations in accordance with the foregoing resolution and the provisions
      of Nevada law.

    
       

      CHINA
        KANGTAI CACTUS BIO-TECH, INC. CERTIFICATE OF
        DESIGNATION

    

    
      
         

      

      
        PAGE
          15 OF 17

        
          

        

      

      
         

      

    

     

    IN
      WITNESS WHEREOF, the undersigned have executed this Certificate this 16th day
      of
      July 2008.

    

      
        	
                /s/
                  Jinjiang Wang

              	 	
                /s/
                  Fengxi Lang

              
	
                Name:
                  Jinjiang Wang

              	 	
                Name:
                  Fengxi Lang

              
	
                Title:
                  President and Chief Executive Officer

              	 	
                Title:
                  Secretary

              

      

    

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          16 OF 17

        
          

        

      

      
         

      

    

    ANNEX
      A

    

    NOTICE
      OF
      CONVERSION

    

    (TO
      BE
      EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES 

    OF
      SERIES
      A PREFERRED STOCK)

    

    The
      undersigned hereby elects to convert the number of shares of Series A
      Convertible Preferred Stock indicated below, into shares of common stock, par
      value $0.001 per share (the "Common
      Stock"),
      of
      China Kangtai Cactus Bio-Tech, Inc., a Nevada Company (the "Company"),
      according to the conditions hereof, as of the date written below. If shares
      are
      to be issued in the name of a person other than undersigned, the undersigned
      will pay all transfer taxes payable with respect thereto and is delivering
      herewith such certificates and opinions as reasonably requested by the Company
      in accordance therewith. No fee will be charged to the Holder for any
      conversion, except for such transfer taxes, if any.

    

    Conversion
      calculations:

    

    
      	
              Date
                to Effect Conversion:
                _____________________________________________

            
	 
	
              Number
                of shares of Common Stock owned prior to Conversion:
                _______________

            
	 
	
              Number
                of shares of Series A Preferred Stock to be Converted:
                ________________________

            
	 
	
              Value
                of shares of Series A Preferred Stock to be Converted:
                ____________________

            
	 
	
              Number
                of shares of Common Stock to be Issued:
                ___________________________

            
	 
	
              Certificate
                Number of Series A Preferred Stock attached
                hereto:________________________

            
	 
	
              Number
                of Shares of Series A Preferred Stock represented by attached
                certificate:__________

            
	 
	
              Number
                of shares of Series A Preferred Stock subsequent to Conversion:
                ________________

            

    

    

      
        	
                T
                  Squared Investments LLC 

              
	 	 
	
                By:

              	
                 

              
	
                Name:

              	
                 

              
	
                Title:

              	
                 

              

      

    

     

    CHINA
      KANGTAI CACTUS BIO-TECH, INC.
      CERTIFICATE OF DESIGNATION

    
      
         

      

      
        PAGE
          17 OF 17THE
      SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
      SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"), OR ANY STATE
SECURITIES
      LAWS AND NEITHER SUCH SHARES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD,
      PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT
      WITH RESPECT THERETO IS EFFECTIVE UNDER THE 1933 ACT AND ANY APPLICABLE STATE
      SECURITIES LAWS, OR (2) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE
      1933 ACT.

    

    IN
      ADDITION, A PREFERRED STOCK PURCHASE AGREEMENT DATED AS OF MARCH 21, 2008 (THE
      “PURCHASE AGREEMENT”), A COPY OF WHICH MAY BE OBTAINED FROM THE COMPANY AT ITS
      PRINCIPAL EXECUTIVE OFFICE, CONTAINS CERTAIN ADDITIONAL AGREEMENTS BETWEEN
      THE
      PARTIES WITH RESPECT TO THIS WARRANT.

    

    
      
        

      

    China
      Kangtai Cactus Corporation

    

    COMMON
      STOCK PURCHASE WARRANT “A”

    

    
      	
              Number
                of Shares:

            	
              500,000

            	
              Holder:
                T Squared Investments LLC

            
	 	 	
              c/o
                T Squared Capital LLC

            
	
              Original
                Issue Date:

            	
              July
                16, 2008

            	
              Attn:
                Thomas M. Sauve

            
	 	 	
              Title:
                Managing Member

            
	
              Expiration
                Date:

            	
              July
                15, 2011

            	
              1325
                Sixth Avenue, Floor 28

            
	 	 	
              New
                York, NY 10019

            
	
              Exercise
                Price per Share:

            	
              $0.9375

            	
              Tel:
                212-763-8615

            
	 	 	
              Fax:
                212-671-1403

            

    

    

    China
      Kangtai Cactus Bio-Tech, Inc., a company organized and existing under the laws
      of the State of Nevada (the “Company”),
      hereby certifies that, for value received, T
      Squared Investments LLC,
      or its
      registered assigns (the “Warrant
      Holder”),
      is
      entitled, subject to the terms set forth below, to purchase from the Company
      up
      to Five Hundred Thousand (500,000) shares (as adjusted from time to time as
      provided in Section 7, the “Warrant
      Shares”)
      of
      common stock, $.001 par value (the “Common
      Stock”),
      of
      the Company at a price $0.9375 per Warrant Share (as adjusted from time to
      time
      as provided in Section 7, the “Exercise
      Price”),
      at
      any time and from time to time from and after the date thereof and through
      and
      including 5:00 p.m. New York City time on July 16, 2011 (or eighteen months
      of effectiveness of a Registration Statement subsequent to the issuance hereof
      (such eighteen months to be extended by one month for each month or portion
      of a
      month during which a Registration Statement’s effectiveness has lapsed or been
      suspended), whichever is longer) (the “Expiration Date”), and subject to the
      following terms and conditions:

    

    WARRANT
      “A” AGREEMENT BETWEEN CHINA KANGTAI CACTUS BIO-TECH, INC.

    AND
      T SQUARED INVESTMENTS LLC

    PAGE
      1OF
      9

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    1. Registration
      of Warrant.
      The
      Company shall register this Warrant upon records to be maintained by the Company
      for that purpose (the “Warrant
      Register”),
      in
      the name of the record Warrant Holder hereof from time to time. The Company
      may
      deem and treat the registered Warrant Holder of this Warrant as the absolute
      owner hereof for the purpose of any exercise hereof or any distribution to
      the
      Warrant Holder, and for all other purposes, and the Company shall not be
      affected by notice to the contrary.

     

    2. Investment
      Representation.
      The
      Warrant Holder by accepting this Warrant represents that the Warrant Holder
      is
      acquiring this Warrant for its own account or the account of an affiliate for
      investment purposes and not with the view to any offering or distribution and
      that the Warrant Holder will not sell or otherwise dispose of this Warrant
      or
      the underlying Warrant Shares in violation of applicable securities laws. The
      Warrant Holder acknowledges that the certificates representing any Warrant
      Shares will bear a legend indicating that they have not been registered under
      the United States Securities Act of 1933, as amended (the “1933
      Act”)
      and
      may not be sold by the Warrant Holder except pursuant to an effective
      registration statement or pursuant to an exemption from registration
      requirements of the 1933 Act and in accordance with federal and state securities
      laws. If this Warrant was acquired by the Warrant Holder pursuant to the
      exemption from the registration requirements of the 1933 Act afforded by
      Regulation S thereunder, the Warrant Holder acknowledges and covenants that
      this
      Warrant may not be exercised by or on behalf of a Person during the one year
      distribution compliance period (as defined in Regulation S) following the date
      hereof. “Person”
      means an
      individual, partnership, firm, limited liability company, trust, joint venture,
      association, corporation, or any other legal entity.

     

    3. Validity
      of Warrant and Issue of Shares.
      The
      Company represents and warrants that this Warrant has been duly authorized
      and
      validly issued and warrants and agrees that all of Common Stock that may be
      issued upon the exercise of the rights represented by this Warrant will, when
      issued upon such exercise, be duly authorized, validly issued, fully paid and
      nonassessable and free from all taxes, liens and charges with respect to the
      issue thereof. The Company further warrants and agrees that during the period
      within which the rights represented by this Warrant may be exercised, the
      Company will at all times have authorized and reserved a sufficient number
      of
      Common Stock to provide for the exercise of the rights represented by this
      Warrant.

     

    4. Registration
      of Transfers and Exchange of Warrants.

     

    a. Subject
      to compliance with the legend set forth on the face of this Warrant, the Company
      shall register the transfer of any portion of this Warrant in the Warrant
      Register, upon surrender of this Warrant with the Form of Assignment attached
      hereto duly completed and signed, to the Company at the office specified in
      or
      pursuant to Section 12. Upon any such registration or transfer, a new warrant
      to
      purchase Common Stock, in substantially the form of this Warrant (any such
      new
      warrant, a “New
      Warrant”),
      evidencing the portion of this Warrant so transferred shall be issued to the
      transferee and a New Warrant evidencing the remaining portion of this Warrant
      not so transferred, if any, shall be issued to the transferring Warrant Holder.
      The acceptance of the New Warrant by the transferee thereof shall be deemed
      the
      acceptance of such transferee of all of the rights and obligations of a Warrant
      Holder of a Warrant.

    

    WARRANT
      “A” AGREEMENT BETWEEN CHINA KANGTAI CACTUS BIO-TECH, INC.

    AND
      T SQUARED INVESTMENTS LLC

    PAGE
      2 OF
      9

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    b. This
      Warrant is exchangeable, upon the surrender hereof by the Warrant Holder to
      the
      office of the Company specified in or pursuant to Section 9 for one or more
      New
      Warrants, evidencing in the aggregate the right to purchase the number of
      Warrant Shares which may then be purchased hereunder. Any such New Warrant
      will
      be dated the date of such exchange.

     

    
      
        5.
          Exercise
          of Warrants.

      

    

     

    a. Upon
      surrender of this Warrant with the Form of Election to Purchase attached hereto
      duly completed and signed to the Company, at its address set forth in Section
      12, and upon payment and delivery of the Exercise Price per Warrant Share
      multiplied by the number of Warrant Shares that the Warrant Holder intends
      to
      purchase hereunder, in lawful money of the United States of America, in cash
      or
      by certified or official bank check or checks, to the Company, all as specified
      by the Warrant Holder in the Form of Election to Purchase, the Company shall
      promptly (but in no event later than 7 business days after the Date of Exercise
      (as defined herein)) issue or cause to be issued and cause to be delivered
      to or
      upon the written order of the Warrant Holder and in such name or names as the
      Warrant Holder may designate (subject to the restrictions on transfer described
      in the legend set forth on the face of this Warrant), a certificate for the
      Warrant Shares issuable upon such exercise, with such restrictive legend as
      required by the 1933 Act. Any person so designated by the Warrant Holder to
      receive Warrant Shares shall be deemed to have become holder of record of such
      Warrant Shares as of the Date of Exercise of this Warrant.

     

    b. A
“Date
      of Exercise” means the date on which the Company shall have received (i) this
      Warrant (or any New Warrant, as applicable), with the Form of Election to
      Purchase attached hereto (or attached to such New Warrant) appropriately
      completed and duly signed, and (ii) payment of the Exercise Price for the number
      of Warrant Shares so indicated by the Warrant Holder to be
      purchased.

     

    c. This
      Warrant shall be exercisable at any time and from time to time for such number
      of Warrant Shares as is indicated in the attached Form of Election To Purchase.
      If less than all of the Warrant Shares which may be purchased under this Warrant
      are exercised at any time, the Company shall issue or cause to be issued, at
      its
      expense, a New Warrant evidencing the right to purchase the remaining number
      of
      Warrant Shares for which no exercise has been evidenced by this
      Warrant.

     

    d. 
      (i) Notwithstanding
      anything contained herein to the contrary but subject to Section 6, the holder
      of this Warrant may, should a registration statement pursuant to the
      Registration Agreement not be made effective within 120 days post Closing,
      exercise this Warrant in whole or in part and, in lieu of making the cash
      payment otherwise contemplated to be made to the Company upon such exercise
      in
      payment of the Aggregate Exercise Price, elect instead to receive upon such
      exercise the “Net
      Number”
of
      shares of Common Stock determined according to the following formula (a
“Cashless
      Exercise”):

     

    Net
      Number = (A x (B - C))/B

    

    WARRANT
      “A” AGREEMENT BETWEEN CHINA KANGTAI CACTUS BIO-TECH, INC.

    AND
      T SQUARED INVESTMENTS LLC

    PAGE
      3 OF
      9

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	
            	(ii)	
              For
                purposes of the foregoing formula:

            

    

     

    A=
      the
      total number shares with respect to which this Warrant is then being
      exercised.

     

    B=
      the
      last reported sale price (as reported by Bloomberg) of the Common Stock on
      the
      trading day immediately preceding the date of the Exercise Notice.

     

    C=
      the
      Warrant Exercise Price then in effect at the time of such exercise.

     

    e. The
      holder of this Warrant agrees not to elect a Cashless Exercise for a period
      of
      twelve (12) months. The holder of this Warrant also agrees not to elect a
      Cashless Exercise so long as there is an effective registration statement for
      the Warrant Shares.

     

    f. Provided
      that the Warrant Shares are Registrable Securities (as defined in the
      Registration Rights Agreement) and are registered pursuant to an effective
      registration statement, at any time commencing on the date hereof if the
      Company’s volume weighted average share price over a thirty (30) day period (“30
      Day VWAP”) exceeds $1.90 per share, the Warrant Holder shall be forced to
      exercise this Warrant within thirty (30) calendar days from the date the 30
      Day
      VWAP exceeds $1.90 per share (“Forced Exercise Period”). Any portion of this
      Warrant not exercise during the Forced Exercise Period shall terminate upon
      at
      the end of such period. This clause is also subject to a volume restriction
      of
      approximately 25% of the daily average volume. The Company can not force the
      investor to exercise into more than 4.9% clause below. 

     

    6. Maximum
      Exercise.
      The
      Warrant Holder shall not be entitled to exercise this Warrant
      on a Date of Exercise in connection with that number of shares of Common Stock
      which would be in excess of the sum of (i) the number of shares of Common Stock
      beneficially owned by the Warrant Holder and its affiliates on an exercise
      date,
      and (ii) the number of shares of Common Stock issuable upon the exercise of
      this
      Warrant with respect to which the determination of this limitation is being
      made
      on an exercise date, which would result in beneficial ownership by the Warrant
      Holder and its affiliates of more than 4.9% of the outstanding shares of Common
      Stock on such date. This Section 6 may be waived or amended only with the
      consent of the Holder and the consent of holders of a majority of the shares
      of
      outstanding Common Stock of the Company who are not Affiliates. For the purposes
      of the immediately preceding sentence, the term “Affiliate” shall mean any
      person: (a) that directly, or indirectly through one or more intermediaries,
      controls, or is controlled by, or is under common control with, the Company;
      or
      (b) who beneficially owns (i) any shares of the Company’s Series A Convertible
      Preferred Stock, (ii) the Company’s Common Stock Purchase Warrant “B” dated July
      17, 2008, or (iii) this Warrant. For the purposes of the immediately preceding
      sentence, beneficial ownership shall be determined in accordance with Section
      13(d) of the Securities Exchange Act of 1934, as amended, and Regulation 13d-3
      thereunder.

    

    WARRANT
      “A” AGREEMENT BETWEEN CHINA KANGTAI CACTUS BIO-TECH, INC.

    AND
      T SQUARED INVESTMENTS LLC

    PAGE
      4 OF
      9

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    7. Adjustment
      of Exercise Price and Number of Shares.
      The
      character of the shares of stock or other securities at the time issuable upon
      exercise of this Warrant and the Exercise Price therefore, are subject to
      adjustment upon the occurrence of the following events, and all such adjustments
      shall be cumulative:

     

    a. Adjustment
      for Stock Splits, Stock Dividends, Recapitalizations, Etc.
      The
      Exercise Price of this Warrant and the number of shares of Common Stock or
      other
      securities at the time issuable upon exercise of this Warrant shall be
      appropriately adjusted to reflect any stock dividend, stock split, combination
      of shares, reclassification, recapitalization or other similar event affecting
      the number of outstanding shares of stock or securities.

     

    b. Adjustment
      for Reorganization, Consolidation, Merger, Etc.
      In case
      of any consolidation or merger of the Company with or into any other
      corporation, entity or person, or any other corporate reorganization, in which
      the Company shall not be the continuing or surviving entity of such
      consolidation, merger or reorganization (any such transaction being hereinafter
      referred to as a "Reorganization"),
      then,
      in each case, the holder of this Warrant, on exercise hereof at any time after
      the consummation or effective date of such Reorganization (the "Effective
      Date"),
      shall
      receive, in lieu of the shares of stock or other securities at any time issuable
      upon the exercise of the Warrant issuable on such exercise prior to the
      Effective Date, the stock and other securities and property (including cash)
      to
      which such holder would have been entitled upon the Effective Date if such
      holder had exercised this Warrant immediately prior thereto (all subject to
      further adjustment as provided in this Warrant).

     

    c. Certificate
      as to Adjustments.
      In case
      of any adjustment or readjustment in the price or kind of securities issuable
      on
      the exercise of this Warrant, the Company will promptly give written notice
      thereof to the holder of this Warrant in the form of a certificate, certified
      and confirmed by the Board of Directors of the Company, setting forth such
      adjustment or readjustment and showing in reasonable detail the facts upon
      which
      such adjustment or readjustment is based.

     

    d. The
      Company fails to meet certain earnings per share
      projections.
      In the
      event the Company earns between $0.0670 and $0.0335 (50% Decline) per share
      (where such earnings in this paragraph shall always be defined as earnings
      on a
      pre tax fully diluted basis (including dilution from any options, warrants
      and
      convertible securities) as reported for the audited sixth months ended June
      30,
      2008 from continuing operations before any non-cash items the then current
      Exercise Price to the Investor at the time the audited numbers are reported
      to
      the SEC shall be decrease proportionately by 0% if the pre tax earnings (for
      first six months ended June 30, 2008) are $0.0670 per share or greater and
      by
      50% if the pre tax earnings (for first six months ended June 30, 2008) are
      $0.0335 per share (50% decrease). For example if the earnings are $0.0536 per
      share or less (20% Decline) then the then current Exercise Price to the investor
      shall be reduced by 20%. Such adjustment shall be made automatically within
      five
      business days of the audited numbers being reported to the SEC. 

     

    WARRANT
      “A” AGREEMENT BETWEEN CHINA KANGTAI CACTUS BIO-TECH, INC.

    AND
      T SQUARED INVESTMENTS LLC

    PAGE
      5 OF
      9

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    e. In
      the
      event the Company earns between $0.1559 and $0.0780 (50% Decline) per share
      (where such earnings in this paragraph shall always be defined as earnings
      on a
      pre tax fully diluted basis (including dilution from any options, warrants
      and
      convertible securities) as reported for the audited fiscal year ending 2008
      from
      continuing operations before any non-cash items the then current Exercise Price
      to the Investor at the time the audited numbers are reported to the SEC shall
      be
      decrease proportionately by 0% if the pre tax earnings are $0.1559 per share
      or
      greater and by 50% if the pre tax earnings are $0.0780 per share (50% decrease).
      For example if the earnings are $ 0.1247 per share or less (20% Decline) then
      the then current Exercise Price to the investor shall be reduced by 20%. Such
      adjustment shall be made automatically within five business days of the audited
      numbers being reported to the SEC.

     

    f. The
      Company sells, grants or issues any shares, options, warrants, or any instrument
      convertible into shares or equity in any form below the exercise price per
      share
      of the warrant.
      In the
      event the Company sells, grants or issues any shares, options, warrants, or
      any
      instrument convertible into shares or equity in any form below the current
      exercise price per share of the warrant, then the current exercise price per
      share for the warrant shall be adjusted to a price determined by multiplying
      such exercise price by a fraction, the numerator of which shall be the number
      of
      shares of Common Stock Outstanding (defined below) immediately prior to such
      issuance plus the number of shares of Common Stock that the aggregate
      consideration received by the Company for such issuance would purchase at such
      exercise price; and the denominator of which shall be the number of shares
      of
      Common Stock Outstanding (as defined below) immediately prior to such issuance
      plus the number of shares issued at such issuance. For purposes of this
Section
      7(f),
      the
      term “Common Stock Outstanding” shall mean and include the following: (1)
      outstanding Common Stock, (2) Common Stock issuable upon conversion of
      outstanding Preferred Stock, (3) Common Stock issuable upon exercise of
      outstanding warrants. Shares described in (1) through (4) above shall be
      included whether vested or unvested, whether contingent or non-contingent and
      whether exercisable or not yet exercisable.

     

    8. Fractional
      Shares.
      The
      Company shall not be required to issue or cause to be issued fractional Warrant
      Shares on the exercise of this Warrant. The number of full Warrant Shares that
      shall be issuable upon the exercise of this Warrant shall be computed on the
      basis of the aggregate number of Warrants Shares purchasable on exercise of
      this
      Warrant so presented. If any fraction of a Warrant Share would, except for
      the
      provisions of this Section 8, be issuable on the exercise of this Warrant,
      the
      Company shall, at its option, (i) pay an amount in cash equal to the Exercise
      Price multiplied by such fraction or (ii) round the number of Warrant Shares
      issuable, up to the next whole number.

     

    9. Sale
      or Merger of the Company.
      Upon
      a
      Change in Control, the restriction contained in Section 6 shall immediately
      be
      released and the Warrant Holder will have the right to exercise this Warrant
      concurrently with such Change in Control event. For purposes of this Warrant,
      the term “Change in Control” shall mean a consolidation or merger of the Company
      with or into another company or entity in which the Company is not the surviving
      entity or the sale of all or substantially all of the assets of the Company
      to
      another company or entity not controlled by the then existing stockholders
      of
      the Company in a transaction or series of transactions.

    

    WARRANT
      “A” AGREEMENT BETWEEN CHINA KANGTAI CACTUS BIO-TECH, INC.

    AND
      T SQUARED INVESTMENTS LLC

    PAGE
      6 OF
      9

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    10. Notice
      of Intent to Sell or Merge the Company.
      The
      Company will give Warrant Holder ten (10) business days notice before the event
      of a sale of all or substantially all of the assets of the Company or the merger
      or consolidation of the Company in a transaction in which the Company is not
      the
      surviving entity.

     

    11. Issuance
      of Substitute Warrant.
      In the
      event of a merger, consolidation, recapitalization or reorganization of the
      Company or a reclassification of Company shares of stock, which results in
      an
      adjustment to the number of shares subject to this Warrant and/or the Exercise
      Price hereunder, the Company agrees to issue to the Warrant Holder a substitute
      Warrant reflecting the adjusted number of shares and/or Exercise Price upon
      the
      surrender of this Warrant to the Company.

     

    12. Notice.
      All
      notices and other communications hereunder shall be in writing and shall be
      deemed to have been given (i) on the date they are delivered if delivered in
      person; (ii) on the date initially received if delivered by facsimile
      transmission followed by registered or certified mail confirmation; (iii) on
      the
      date delivered by an overnight courier service; or (iv) on the third business
      day after it is mailed by registered or certified mail, return receipt requested
      with postage and other fees prepaid as follows:

     

    If
      to
      the Company:

     

    China
      Kangtai Cactus Bio-Tech, Inc.

    99
      Taibei
      Road

    Limin
      Economic and Technological Development Zone

    Harbin,
      China 150025

    Attn:
      Jinjiang Wang

    

    If
      to
      the Warrant Holder:

    

    T
      Squared
      Investments LLC

    c/o
      T
      Squared Capital LLC

    1325
      Sixth Avenue, Floor 28

    New
      York,
      New York 10019

    Attn:
      Thomas M. Sauve

    

    
      
        13.
          Miscellaneous.

      

    

     

    a. This
      Warrant shall be binding on and inure to the benefit of the parties hereto
      and
      their respective successors and permitted assigns. This Warrant may be amended
      only by a writing signed by the Company and the Warrant Holder.

     

    b. Nothing
      in this Warrant shall be construed to give to any person or corporation other
      than the Company and the Warrant Holder any legal or equitable right, remedy
      or
      cause of action under this Warrant; this Warrant shall be for the sole and
      exclusive benefit of the Company and the Warrant Holder.

     

    WARRANT
      “A” AGREEMENT BETWEEN CHINA KANGTAI CACTUS BIO-TECH, INC.

    AND
      T SQUARED INVESTMENTS LLC

    PAGE
      7 OF
      9

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    c. This
      Warrant shall be governed by, construed and enforced in accordance with the
      internal laws of the State of New York without regard to the principles of
      conflicts of law thereof.

     

    d. The
      headings herein are for convenience only, do not constitute a part of this
      Warrant and shall not be deemed to limit or affect any of the provisions
      hereof.

     

    e. In
      case
      any one or more of the provisions of this Warrant shall be invalid or
      unenforceable in any respect, the validity and enforceablilty of the remaining
      terms and provisions of this Warrant shall not in any way be affected or
      impaired thereby and the parties will attempt in good faith to agree upon a
      valid and enforceable provision which shall be a commercially reasonably
      substitute therefore, and upon so agreeing, shall incorporate such substitute
      provision in this Warrant.

     

    f. The
      Warrant Holder shall not, by virtue hereof, be entitled to any voting or other
      rights of a shareholder of the Company, either at law or equity, and the rights
      of the Warrant Holder are limited to those expressed in this
      Warrant.

     

    [SIGNATURES
      ON FOLLOWING PAGE]

    

    WARRANT
      “A” AGREEMENT BETWEEN CHINA KANGTAI CACTUS BIO-TECH, INC.

    AND
      T SQUARED INVESTMENTS LLC

    PAGE
      8 OF
      9

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    IN
      WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by
      the
      authorized officer as of the date first above stated.

    

    

    CHINA
      KANGTAI CACTUS BIO-TECH, INC., a Nevada corporation

    

    
      	
              By:
                /s/ Jinjiang Wang

            
	
              Jinjiang
                Wang, President and Chief Executive
                Officer

            

    

    

    

    WARRANT
      “A” AGREEMENT BETWEEN CHINA KANGTAI CACTUS BIO-TECH, INC.

    AND
      T SQUARED INVESTMENTS LLC

    PAGE
      9 OF
      9

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    FORM
      OF ELECTION TO PURCHASE

    

    (To
      be
      executed by the Warrant Holder to exercise the right to purchase shares of
      Common Stock under the foregoing Warrant)

     

    

    To:
      China
      Kangtai Cactus Bio-Tech, Inc.:

    

    In
      accordance with the Warrant enclosed with this Form of Election to Purchase,
      the
      undersigned hereby irrevocably elects to purchase ______________ shares of
      Common Stock (“Common Stock”), $.001 par value, of China Kangtai Cactus
      Bio-Tech, Inc., Inc and encloses the warrant and $____ for each Warrant Share
      being purchased or an aggregate of $________________ in cash or certified or
      official bank check or checks, which sum represents the aggregate Exercise
      Price
      (as defined in the Warrant) together with any applicable taxes payable by the
      undersigned pursuant to the Warrant.

    

    The
      undersigned requests that certificates for the shares of Common Stock issuable
      upon this exercise be issued in the name of:

    

    
      	 
	 
	 
	 
	 
	
              (Please
                print name and address)

            
	 
	 
	
              (Please
                insert Social Security or Tax Identification
                Number)

            

    

    

    If
      the
      number of shares of Common Stock issuable upon this exercise shall not be all
      of
      the shares of Common Stock which the undersigned is entitled to purchase in
      accordance with the enclosed Warrant, the undersigned requests that a New
      Warrant (as defined in the Warrant) evidencing the right to purchase the shares
      of Common Stock not issuable pursuant to the exercise evidenced hereby be issued
      in the name of and delivered to:

    

    
      	 
	 	 
	 
	 	 
	 
	
              (Please
                print name and address)

            
	 	 
	
              Dated:
                

            	 
	 	 
	 	 
	
              Name
                of Warrant Holder:

            
	 	 
	
              (Print)
                

            	 
	 	 
	
              (By:)
                

            	 
	 	 
	
              (Name:)
                

            	 
	 	 
	
              (Title:)
                

            	 

    

    

    Signature
      must conform in all respects to name of Warrant Holder as specified on the
      face
      of the Warrant

    

    WARRANT
      “A” AGREEMENT BETWEEN CHINA KANGTAI CACTUS BIO-TECH, INC.

    AND
      T SQUARED INVESTMENTS LLC

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]